TEMPISIN1234

Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL SpeakersVivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers

Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers

Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers Halle (Saale) / Munich, Germany, February 19, 2025…

1 month ago
Maze Therapeutics Announces Pricing of Upsized Initial Public OfferingMaze Therapeutics Announces Pricing of Upsized Initial Public Offering

Maze Therapeutics Announces Pricing of Upsized Initial Public Offering

January 30, 2025 19:30 ET  | Source: Maze Therapeutics, Inc. SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) --…

2 months ago
Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney DiseaseVivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease

Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease

Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease A meta-analysis of VIVIAD and VIVA-MIND1 data confirmed…

3 months ago
BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of ObesityBioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity

BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity

December 06, 2024 16:35 ET | Source: BioAge Labs, Inc. Decision follows observations of liver transaminitis without clinically significant symptoms…

4 months ago